Jean-Paul Kress Joins Sanofi's Board of Directors
Sanofi is excited to announce that Jean-Paul Kress will join its Board of Directors as an independent director, effective from the start of the new year. This transition comes as he takes over the role from Gilles Schnepp, who has served on the Board and is departing at the end of the current year.
Jean-Paul Kress's Impressive Background
Bringing a wealth of experience, Jean-Paul Kress, M.D., previously served as the CEO of MorphoSys until its recent acquisition by Novartis. Under his leadership, the company made significant strides in developing innovative treatments for cancer, guided by the mission statement, More life for people with cancer. His expertise in the biopharmaceutical sector is underscored not only by his time at MorphoSys but also during his tenure as CEO at Syntimmune, where he led the company’s focus on late-stage clinical programs targeting auto-immune diseases before its acquisition by Alexion.
Future Contributions to Sanofi's Evolution
Frédéric Oudéa, Chairman of Sanofi's Board, expressed his gratitude towards Gilles Schnepp for his dedicated service, especially regarding the enhancement of the company's governance practices throughout 2023. The Board is eager to leverage Jean-Paul's extensive executive experience, which spans over 30 years in various capacities within both major pharmaceutical corporations and biotech firms. His global perspective will undoubtedly be invaluable as Sanofi continues to navigate its strategic evolution in the biopharmaceutical sphere.
Board Committee Appointments
With this new addition to the Board, adjustments in governance responsibilities are also set to occur. Patrick Kron will assume the role of Chairman for the Appointments, Governance, and CSR Committee while Jean-Paul Kress will actively participate in both the Strategy Committee and the Scientific Committee.
About Sanofi
Sanofi is a prominent global healthcare organization committed to harnessing advances in science to enhance lives. The company is dedicated to revolutionizing medical practices and providing revolutionary treatment options and crucial vaccines to millions globally. Central to Sanofi's mission is a commitment to sustainability and social responsibility, reflecting its dedication to making a positive impact on the health of individuals and communities.
Media Relations Contacts
For media inquiries, Sanofi has a dedicated team available for contact:
- Sandrine Guendoul | + 33 6 25 09 14 25
- Evan Berland | +1 215 432 0234
- Nicolas Obrist | + 33 6 77 21 27 55
- Léo Le Bourhis | + 33 6 75 06 43 81
- Victor Rouault | + 33 6 70 93 71 40
- Timothy Gilbert | + 1 516 521 2929
Investor Relations Contact Information
Investors can also reach out to Sanofi's Investor Relations team:
- Thomas Kudsk Larsen | + 44 7545 513 693
- Alizé Kaisserian | + 33 6 47 04 12 11
- Felix Lauscher | + 1 908 612 7239
- Keita Browne | + 1 781 249 1766
- Nathalie Pham | + 33 7 85 93 30 17
- Tarik Elgoutni | + 1 617 710 3587
- Thibaud Châtelet | + 33 6 80 80 89 90
Frequently Asked Questions
What role will Jean-Paul Kress have on Sanofi's Board?
Jean-Paul Kress will serve as an independent director, replacing Gilles Schnepp, whose term ends soon.
What previous experience does Jean-Paul Kress bring?
Jean-Paul Kress has extensive experience as a CEO in biopharmaceuticals, previously leading MorphoSys and Syntimmune.
How does Sanofi benefit from Kress's expertise?
His 30 years of global experience in the pharmaceutical industry will enhance the strategic direction of Sanofi.
What committees will Kress join?
Kress will have roles on the Strategy Committee and the Scientific Committee as part of his contribution.
How does Sanofi uphold its mission?
Sanofi is committed to advancing healthcare through innovation and prioritizes sustainability and social responsibility in its operations.
